• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session

    12/30/22 12:28:11 PM ET
    $ALLR
    $AXDX
    $BLNK
    $CCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ALLR alert in real time by email

    Gainers

    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contemplated public offering.
    • Palisade Bio, Inc. (NASDAQ:PALI) shares jumped 80.1% to $5.80. Palisade Bio announced $2.5 million registered direct offering and concurrent private placement priced above market under Nasdaq rules.
    • Silo Pharma, Inc. (NASDAQ:SILO) gained 63.7% to $5.60 after the company announced study results of SPU-21 for arthritis. The company said SPU-21 is effective in controlling arthritis progression.
    • F-star Therapeutics, Inc. (NASDAQ:FSTX) shares gained 42.8% to $5.84. F-Star Therapeutics shares traded lower on Thursday after the Committee on Foreign Investment issued an interim order preventing the closing of the pending merger with Invox Pharma.
    • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) jumped 38% to $33.65. Kala Pharmaceuticals recently announced FDA acceptance of an IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
    • Charah Solutions, Inc. (NYSE:CHRA) gained 37.6% to $5.57. Charah Solutions reported receipt of notification letter from NYSE.
    • Embark Technology, Inc. (NASDAQ:EMBK) gained 33% to $3.4686.
    • NovaBay Pharmaceuticals, Inc. (NYSE:NBY) jumped 27.3% to $1.77.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) jumped 26.7% to $0.3679.
    • Concord Medical Services Holdings Limited (NYSE:CCM) gained 23.8% to $1.6599.
    • Mereo BioPharma Group plc (NASDAQ:MREO) surged 23.6% to $0.69.
    • 9 Meters Biopharma, Inc. (NASDAQ:NMTR) gained 23% to $1.4450.
    • Frequency Therapeutics, Inc. (NASDAQ:FREQ) jumped 22.5% to $3.97.
    • Journey Medical Corporation (NASDAQ:DERM) surged 22% to $1.77. Journey Medical recently announced PK comparability data of DFD-29 and key updates on the progress of its pivotal, Phase 3 study of DFD-29 for papulopustular rosacea in collaboration with Dr. Reddy's Laboratories.
    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) gained 21% to $1.3988.
    • Protagenic Therapeutics, Inc. (NASDAQ:PTIX) gained 20% to $0.42.
    • Tuesday Morning Corporation (NASDAQ:TUEM) rose 19.8% to $0.8195 after gaining around 16% on Thursday. Tuesday Morning recently announced it will voluntarily delist from the Nasdaq Capital Market.
    • ECARX Holdings Inc. (NASDAQ:ECX) gained 17.8% to $8.00.
    • BitNile Holdings, Inc. (NYSE:NILE) surged 17.5% to $0.1175. BitNile Holdings, Inc. reported Ault Alpha has purchased 50m shares of the company's common stock.
    • Histogen Inc. (NASDAQ:HSTO) gained 17.5% to $0.94.
    • Sesen Bio, Inc. (NASDAQ:SESN) shares rose 16.8% to $0.59 after the company and Carisma Therapeutics announced an increased special dividend of $70 million, or $0.34 per share, in connection with the pending merger.
    • Scholar Rock Holding Corporation (NASDAQ:SRRK) gained 15.8% to $9.35.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) rose 15.3% to $0.6012.
    • Getaround, Inc. (NYSE:GETR) rose 13.5% to $0.5676 after dropping around 8% on Thursday. Piper Sandler initiated coverage on Getaround with an Overweight rating and announced a price target of $1.5.
    • NaaS Technology Inc. (NASDAQ:NAAS) gained 12.9% to $3.3758. NaaS Technology appointed Alex Wu as its Chief Financial Officer, effective January 15, 2023.
    • EZGO Technologies Ltd. (NASDAQ:EZGO) surged 12% to $0.58.
    • Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) gained 11.8% to $0.2025.
    • The Lion Electric Company (NYSE:LEV) gained 11.5% to $2.31.
    • Lightning eMotors, Inc. (NYSE:ZEV) shares rose 11.1% to $0.3629. Lightning eMotors recently received continued listing standards notice from NYSE.
    • Kineta, Inc. (NASDAQ:KA) gained 9.8% to $6.71.
    • Shaw Communications Inc. (NYSE:SJR) rose 9.3% to $28.91 following the decision summary by the Competition Tribunal allowing the proposed acquisition of Freedom Mobile by Videotron, and the subsequent combination of Rogers and Shaw to proceed.
    • Blink Charging Co. (NASDAQ:BLNK) gained 9.1% to $11.12.
    • Rogers Communications Inc. (NYSE:RCI) surged 5.6% to $47.61.

     

    Losers

    • Futu Holdings Limited (NASDAQ:FUTU) fell 24.8% to $44.27. Tencent Holding backed Chinese online broker Futu Holdings unexpectedly deferred its Hong Kong listing less than a day before its anticipated debut on December 30.
    • UP Fintech Holding Limited (NASDAQ:TIGR) shares dipped 24% to $3.63 after the China Securities Regulatory Commission reported the companies have conducted illegal securities business.
    • Scilex Holding Company (NASDAQ:SCLX) dropped 22% to $3.1189.
    • Hoth Therapeutics, Inc. (NASDAQ:HOTH) fell 19% to $8.69 after the company announced a $10 million private placement priced at-the-market under Nasdaq rules.
    • Shineco, Inc. (NASDAQ:SISI) dropped 17.4% to $1.85.
    • ReShape Lifesciences Inc. (NASDAQ:RSLS) fell 17.2% to $6.36. Reshape Lifesciences recently announced a 1-for-50 reverse stock split.
    • Secoo Holding Limited (NASDAQ:SECO) dropped 11.7% to $1.88.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) dropped 11.3% to $0.5058. TransCode Therapeutics recently announced it received written authorization from the FDA that it may proceed with its First-in-Human Phase 0 clinical trial.
    • Drive Shack Inc. (NYSE:DS) dropped 10.2% to $0.1870. Drive Shack recently announced the intention to voluntarily delist and deregister its securities.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) dipped 9.9% to $0.5665.
    • Unicycive Therapeutics, Inc. (NASDAQ:UNCY) dropped 9.8% to $0.4990. Unicycive recently announced termination of 'at-the-market' offering of shares of common stock.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) shares fell 8.9% to $0.1753 after declining around 20% on Thursday. Rubius Therapeutics, last month, initiated a process to explore a range of strategic alternatives and plans to engage an investment bank to act as a strategic advisor for this process.
    • Quotient Limited (NASDAQ:QTNT) fell 6.5% to $0.3460 after jumping 54% on Thursday.

    Also Check This Out $2.5 Million Bet On CrowdStrike Holdings? Check Out These 4 Stocks Insiders Are Buying

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $AXDX
    $BLNK
    $CCM

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Futu Holdings Limited
    $FUTU
    2/2/2026$213.39Neutral → Buy
    Goldman
    Scholar Rock Holding Corporation
    $SRRK
    1/9/2026$55.00Buy
    Citigroup
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Rogers Communication Inc.
    $RCI
    12/10/2025Buy → Hold
    Desjardins
    Futu Holdings Limited
    $FUTU
    11/21/2025$201.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ALLR
    $AXDX
    $BLNK
    $CCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Futu Holdings upgraded by Goldman with a new price target

    Goldman upgraded Futu Holdings from Neutral to Buy and set a new price target of $213.39

    2/2/26 6:47:07 AM ET
    $FUTU
    Investment Bankers/Brokers/Service
    Finance

    Citigroup initiated coverage on Scholar Rock with a new price target

    Citigroup initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $55.00

    1/9/26 9:07:37 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AXDX
    $BLNK
    $CCM
    SEC Filings

    View All

    Dermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    2/25/26 4:05:32 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagenic Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

    2/23/26 8:49:28 PM ET
    $PTIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/23/26 7:56:24 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AXDX
    $BLNK
    $CCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Qatanani Mo sold $399,351 worth of shares (8,484 units at $47.07), decreasing direct ownership by 8% to 98,445 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/25/26 5:55:24 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENERAL COUNSEL Ho Junlin sold $445,740 worth of shares (9,580 units at $46.53), decreasing direct ownership by 4% to 241,545 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/19/26 4:30:12 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF MEDICAL OFFICER Marantz Jing L. sold $193,418 worth of shares (4,157 units at $46.53), decreasing direct ownership by 3% to 126,012 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/19/26 4:30:14 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AXDX
    $BLNK
    $CCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Akkaraju Srinivas bought $1,181,634 worth of shares (29,599 units at $39.92) and exercised 1,064,804 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    12/16/25 9:07:57 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AXDX
    $BLNK
    $CCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    moomoo Serves as First Brokerage Platform for Retail Access to Figure Technology Solutions Inc.'s blockchain-native share offering

    JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- moomoo, a global investment and trading platform, today announced that it was the first U.S. brokerage firm to provide retail investor access to Figure Technology Solutions Inc.'s blockchain-native share offering. The offering represents the first SEC-registered public equity issued in blockchain-native form. The transaction reflects moomoo's continued focus on enabling retail participation in new issuance formats for public equity, rather than new asset classes, while maintaining compliance with applicable U.S. securities regulations. Customers participated using U.S. dollar buying power through their existing moomoo brokerage accounts

    2/26/26 12:00:00 PM ET
    $FUTU
    Investment Bankers/Brokers/Service
    Finance

    HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

    CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment OptionNEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites — a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.

    2/24/26 4:15:00 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moomoo and W!se Award $10,000 to Queens Gateway to Health Sciences Secondary School as Part of Student Stock Showdown Challenge

    JERSEY CITY, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Moomoo, a leading global investment and trading platform, today named Queens Gateway to Health Sciences Secondary School the winning school in the Student Stock Showdown challenge, a 13-week paper trading competition delivered in partnership with Working in Support of Education (W!se), an educational nonprofit based in New York City. The recognition honors Queens Gateway's strong overall performance and student engagement throughout the program, which brought real-world investing concepts into high school classrooms across New York. The Student Stock Showdown provided students with a fully simulated, risk-free investing experience power

    2/24/26 8:00:00 AM ET
    $FUTU
    Investment Bankers/Brokers/Service
    Finance

    $ALLR
    $AXDX
    $BLNK
    $CCM
    Financials

    Live finance-specific insights

    View All

    Futu to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Futu Holdings Limited ("Futu" or the "Company") (NASDAQ:FUTU), a leading tech-driven online brokerage and wealth management platform, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before U.S. markets open on March 12, 2026. Futu's management will hold an earnings conference call on Thursday, March 12, 2026, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Please note that all participants will need to pre-register for the conference call, using the link https://register-conf.media-server.com/register/BIe49e3331c0f24a9d9926d5b979ab55df It

    2/24/26 3:00:00 AM ET
    $FUTU
    Investment Bankers/Brokers/Service
    Finance

    Scholar Rock to Present at Upcoming Investor Conferences

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:50 p.m. ET on Wednesday, March 4, 2026 in Boston, MA Leerink Partners 2026 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:

    2/18/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us

    2/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AXDX
    $BLNK
    $CCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NaaS Technology Inc.

    SC 13G/A - NaaS Technology Inc. (0001712178) (Subject)

    11/14/24 9:58:25 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    $ALLR
    $AXDX
    $BLNK
    $CCM
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care